Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications

World Journal of Gastroenterology

Volumn 18, Issue 24, 2012, Pages 3167-3172

  Zhu, Ling Ling ^a   Xu, Ling Cheng ^b   Chen, Yan ^b   Zhou, Quan ^b   Zeng, Su ^c  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Combined medications; Defined daily dose; Drug utilization; Gastrointestinal injury; Histamine 2 receptor antagonists; Low dose aspirin; Mucoprotective drugs; Prescribing patterns; Proton pump inhibitors; Small bowel injury

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CORTICOSTEROID; DEXAMETHASONE; ESOMEPRAZOLE; GEFARNATE; GLUTAMINE; GUALENATE SODIUM; HYDROTALCITE; METHYLPREDNISOLONE; MISOPROSTOL; OMEPRAZOLE; PANTOPRAZOLE; PREDNISONE; RABEPRAZOLE; REBAMIPIDE; SUCRALFATE; TEPRENONE; WARFARIN;

ARTICLE; DIGESTIVE SYSTEM INJURY; DRUG INDUCED DISEASE; DRUG UTILIZATION; HUMAN; PHYSICIAN ATTITUDE; PRESCRIPTION; RETROSPECTIVE STUDY; UPPER GASTROINTESTINAL BLEEDING;

EID: 84863963790     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i24.3167     Document Type: Article

References (27)

1. Mizukami K, Murakami K, Abe T, Inoue K, Uchida M, Okimoto T, Kodama M, Fujioka T. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 2011; 17: 5117-5122.
2. Hiraishi H, Maeda M, Sasai T, Kanke K, Shimada T. [Strategy to manage low dose aspirin-induced gastrointestinal injury]. Nihon Rinsho 2011; 69: 369-375.
3. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011; 123: 1108-1115.
4. Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a metaanalysis. Clin Gastroenterol Hepatol 2011; 9: 762-768.e6.
5. Yamamoto T, Isono A, Mishina Y, Ebato T, Shirai T, Nakayama S, Nagasawa K, Abe K, Hattori K, Ishii T, Kuyama Y. Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. J Clin Biochem Nutr 2010; 47: 27-31.
6. Ono S, Kato M, Imai A, Yoshida T, Hirota J, Hata T, Takagi K, Kamada G, Ono Y, Nakagawa M, Nakagawa S, Shimizu Y, Takeda H, Asaka M. Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr 2009; 45: 248-253.
7. Nema H, Kato M. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J Gastroenterol 2010; 16: 5342-5346.
8. Barozzi N, Tett SE. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing. Clin Ther 2009; 31: 849-861.
9. Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Higuchi K, Arakawa T. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6: 1279-1282.
10. Fujimori S, Takahashi Y, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. Prevention of traditional NSAID-induced small intestinal injury: recent preliminary studies using capsule endoscopy. Digestion 2010; 82: 167-172.
11. Nishida U, Kato M, Nishida M, Kamada G, Yoshida T, Ono S, Shimizu Y, Asaka M. Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin. World J Gastroenterol 2011; 17: 226-230.
12. Niwa Y, Nakamura M, Miyahara R, Ohmiya N, Watanabe O, Ando T, Kawashima H, Itoh A, Hirooka Y, Goto H. Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study. Digestion 2009; 80: 260-266.
13. Iwai T, Ichikawa T, Kida M, Goso Y, Kurihara M, Koizumi W, Ishihara K. Protective effect of geranylgeranylacetone against loxoprofen sodium-induced small intestinal lesions in rats. Eur J Pharmacol 2011; 652: 121-125.
14. Fang L, Lv B, Meng LN, Zhang S, Wu WF. Preventive effects of different drugs on intestinal damage induced by non-steroidal anti-infammatory drugs in rats. Shijie Huaren Xiaohua Zazhi 2009; 17: 3244-3248.
15. Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009; 69: 51-69.
16. Nakashima S, Ota S, Arai S, Yoshino K, Inao M, Ishikawa K, Nakayama N, Imai Y, Nagoshi S, Mochida S. Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. World J Gastroenterol 2009; 15: 727-731.
17. Fontes-Carvalho R, Albuquerque A, Araújo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol 2011; 23: 396-404.
18. Neubauer H, Engelhardt A, Krüger JC, Lask S, Börgel J, Mügge A, Endres HG. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol 2010; 56: 91-97.
19. Kenngott S, Olze R, Kollmer M, Bottheim H, Laner A, Holinski-Feder E, Gross M. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur J Med Res 2010; 15: 220-224.
20. Tunggal P, Ng FH, Lam KF, Chan FK, Lau YK. Effect of eso meprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J 2011; 162: 870-874.
21. Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T, Okabe S. Effects of the antiulcer drug geranylgeranylacetone on aspirin-induced gastric ulcers in rats. Jpn J Pharmacol 1982; 32: 299-306.
22. Shiotani A, Haruma K, Nishi R, Fujita M, Kamada T, Honda K, Kusunoki H, Hata J, Graham DY. Randomized, doubleblind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol 2010; 45: 292-298.
23. Sugano K, Matsumoto Y, Itabashi T, Abe S, Sakaki N, Ashida K, Mizokami Y, Chiba T, Matsui S, Kanto T, Shimada K, Uchiyama S, Uemura N, Hiramatsu N. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 2011; 46: 724-735.
24. 2, nitric oxide and redox status in indomethacin-induced gastric ulcer model. Eur J Pharmacol 2010; 649: 314-319.
25. Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000; 14: 529-534.
26. Laine L. Review article: gastrointestinal bleeding with lowdose aspirin what's the risk? Aliment Pharmacol Ther 2006; 24: 897-908.
27. Coté GA, Rice JP, Bulsiewicz W, Norvell JP, Christensen K, Bobb A, Postelnick M, Howden CW. Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users. Am J Gastroenterol 2008; 103: 1097-1103.